News

The status of emergency departments in the city during the pandemic's migration west.

Deaths associated with pneumoconiosis fell 40% from 1999 to 2018, with the greatest decrease among coal workers cases, according to a new report.

Bradley Sherman, MD, shares insight as to what goes into a respiratory ventilator recovery unit.

“Anti-Viral Immune Enhancement” also recalled due to unsubstantiated coronavirus claims.

Four human coronavirus infection rates were relatively consistent among all age groups older than 4 years, the study also found.

The infectious disease pharmaceutical and medical device pipeline is always evolving. See a round-up of our FDA drug pipeline coverage from the past week:

While smallpox may not be in headlines today, the illness (treated with tecovirimat) remains a threat.

Dr. Luwy Musey, executive director in biologics, Merck Research Laboratories, discusses what clinicians need to know about the latest PCVs.

A look at how the state became a belated hotspot, and what may help reduce future infection growth.

A group of scientists hypothesize these shots could protect young children from the novel virus.

A European study shows a small amount of hospitalized children and adolescents with COVID-19 require intensive care and is rarely fatal.

A brief on today's top ID news.

The Hong Kong researchers used online searches to quantify public interest in mask usage.

In a joint-interview, we discuss the PCV pipeline with Dr. Luwy Musey (of Merck & Co.) and Dr. Steven Pelton.

The finger-prick test showed 98.8% specificity for novel coronavirus in assessments including 1500 patients.

Analysis suggests approach may be particularly useful when testing resources are limited.

Where did things go wrong for the Grand Canyon State?

A high proportion of N95 masks failed to fit properly with the extended use and reuse recommended by the CDC for conserving PPE during the shortage.

Video briefing on the day's top infectious disease news.

Given research into SARS-CoV-2 is taking place at unprecedented speed, the panel of IDSA experts had to decide on current best practices using science which is still in motion.

New research shows microorganisms on this part of the body may be able to diagnose chronic heart failure.

In a small randomized trial, Greek investigators found patients had improved time to clinical deterioration versus a control group.

Patrick Soon-Shiong, MD, Chairman and CEO of ImmunityBio, explains why the firm's COVID-19 research benefits from drawing on a background in cancer.

A recent review of electronic health data revealed a 42% drop in emergency department visits during 4 weeks of the pandemic.

RSV-associated lower respiratory infections affect tens of millions of children and kill more than 100,000 children each year. A new vaccine candidate is showing promise in protecting against the disease.

An overview of today's top infectious disease stories.

Patrick Soon-Shiong, MD, CEO of ImmunityBio, discusses the pandemic as a unique moment in world & American history.

In order to expand the potential uses of the drug against SARS-CoV-2, Gilead Sciences has announced plans to explore administration of remdesivir in an inhaled form.

Finch Therapeutics announced its investigational oral microbiome drug, CP101, reached a sustained clinical cure in its Phase 2 trial.

Data were published using the International Symposium on Pneumococci and Pneumococcal Diseases online digital library.